Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.96
-0.83 (-5.61%)
At close: Oct 28, 2025, 4:00 PM EDT
14.26
+0.30 (2.15%)
Pre-market: Oct 29, 2025, 4:25 AM EDT
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $14.25M in the quarter ending June 30, 2025, with 104.76% growth. This brings the company's revenue in the last twelve months to $52.86M, up 14.99% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$52.86M
Revenue Growth
+14.99%
P/S Ratio
27.08
Revenue / Employee
$131,159
Employees
403
Market Cap
1.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NTLA News
- 1 day ago - Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript - Seeking Alpha
- 1 day ago - Intellia pauses late-stage trials of gene-editing treatment after serious liver event - Reuters
- 1 day ago - Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - GlobeNewsWire
- 4 days ago - Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook - Seeking Alpha
- 25 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug - Benzinga
- 4 weeks ago - Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis - Seeking Alpha